Industries · Dermatology & Cosmetics
From ex vivo skin explants to microbiome swabs, OMICS4 runs the molecular evidence behind your efficacy claims and mechanism-of-action studies, in-house and through our dermo-cosmetic partner network.
Platforms used in this field
Overview
OMICS4 runs the bench work behind dermo-cosmetic studies: ex vivo explants sequenced, skin microbiome profiled, low-biomass material handled without losing the signal. Primary data comes back quality-controlled, iteration after iteration, on the same protocol.
Platforms
Bulk RNA sequencing of ex vivo skin explants.
16S and shotgun profiling of the skin community.
Protocols tuned for low-input and low-biomass material.
Targeted measurement across a formulation series.
Ex vivo skin explants, biopsies, swabs, tape strips and culture supernatant. Low-biomass sampling is where a standard extraction loses the signal, so the protocol is chosen by matrix. Collection and storage protocols, and the RNA criteria that apply after extraction, are published per sample type.
Ex vivo explant studies run with DIVA Expertise and PKDERM, under the same single point of contact and the same QC standards as our in-house platforms. Formulation programmes advance in cycles, so the protocol is held fixed across a series: that is the only way one iteration can be compared with the next.
A QC report for every sample. Sequencing files and, where the service covers it, aligned and quantified outputs. Result tables for PCR and protein work. Exports in the formats your team already imports, and turnaround published per service.
Analysis, integration, biomarker discovery and modelling are not part of a platform booking. They are run by GenXMap’s computational team. Ask for them in the quote request and both are scoped together.
Analysis at GenXMapHave a project in this space?